Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 28;14:17588359221105020. doi: 10.1177/17588359221105020

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Efficacy of selpercatinib in pretreated and treatment-naïve patients with RET fusion-positive NSCLC. Waterfall plots showing the maximum change in tumor size in all target lesions in the PAS (n = 26; a) and in all enrolled patients with NSCLC (n = 47; b) according to IRC assessment. Waterfall plots only show patients with measurable target lesions. One patient in the PAS and two patients of all enrolled patients with NSCLC had nonmeasurable disease.

IRC, independent review committee; NSCLC, non-small-cell lung cancer; PAS, primary analysis set.